Details

Autor(en) / Beteiligte

• Lukowiak, Tess M.
• Perz, Allison M.
• Aizman, Leora
• Kovell, Robert Caleb
• Kovach, Stephen
• Fischer, John P.
• Krausz, Aimee
• Giordano, Cerrene
• Higgins, H. William
• Shin, Thuzar M.
• Sobanko, Joseph F.
• Etzkorn, Jeremy R.
• McMurray, Stacy
• Chelluri, Raju
• Guzzo, Thomas
• Miller, Christopher J.

Titel

Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes

Ist Teil von

• Journal of the American Academy of Dermatology, 2021-04, Vol.84 (4), p.1030-1036

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• Local recurrence rates (LRRs) after Mohs micrographic surgery (MMS) for male genital cancers have been reported in only a few small case series, and patient-reported outcomes (PROs) have not been studied. To determine the LRR and PROs after MMS for male genital skin cancers. Retrospective review of all male genital skin cancers removed with MMS between 2008 and 2019 at an academic center. LRR was determined by chart review and phone calls. PROs were assessed by survey. A total of 119 skin cancers in 108 patients were removed with MMS. Tumors were located on the penis (90/119) and scrotum (29/119). Diagnoses included squamous cell carcinoma in situ (n = 71), invasive squamous cell carcinoma (n = 32), extramammary Paget disease (n = 13), melanoma (n = 2), and basal cell carcinoma (n = 1). The LRR was 0.84% (1/119), with a mean follow-up time of 3.25 years (median, 2.36 years). The majority of survey respondents reported no changes in urinary (66%) or sexual functioning (57.5%) after surgery. Retrospective single-center experience; short follow-up time; low survey response rate; no baseline functional data. MMS for male genital skin cancer has a low LRR and high patient-reported satisfaction with urinary and sexual function.